AN2 Therapeutics Files 8-K on Operations & Financials
Ticker: ANTX · Form: 8-K · Filed: Mar 25, 2025 · CIK: 1880438
Sentiment: neutral
Topics: 8-K, financials, operations
Related Tickers: ANTX
TL;DR
AN2 Therapeutics filed an 8-K on March 25, 2025, covering operations and financials.
AI Summary
AN2 Therapeutics, Inc. filed an 8-K on March 25, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.
Why It Matters
This filing indicates AN2 Therapeutics is providing updates on its financial status and operational results to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K to report on operations and financial condition, without disclosing new material events or significant financial changes.
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- 0000950170-25-044353 (filing_id) — Accession Number
- March 25, 2025 (date) — Filing Date
- 1800 El Camino Real, Suite D, Menlo Park, CA 94027 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by AN2 Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on AN2 Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to include Financial Statements and Exhibits.
On what date was this 8-K filing made?
This 8-K filing was made on March 25, 2025.
What is the exact name of the company filing this report?
The exact name of the company filing this report is AN2 Therapeutics, Inc.
Where are AN2 Therapeutics, Inc.'s principal executive offices located?
AN2 Therapeutics, Inc.'s principal executive offices are located at 1800 El Camino Real, Suite D, Menlo Park, California, 94027.
What is the Commission File Number for AN2 Therapeutics, Inc.?
The Commission File Number for AN2 Therapeutics, Inc. is 001-41331.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 25, 2025 regarding AN2 Therapeutics, Inc. (ANTX).